Technology | February 17, 2026
Duvakitug was well tolerated and safety was consistent with the induction study
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
Subscribe To Our Newsletter & Stay Updated
